201 related articles for article (PubMed ID: 2838428)
1. Protection against herpetic ocular disease by immunotherapy with monoclonal antibodies to herpes simplex virus glycoproteins.
Metcalf JF; Chatterjee S; Koga J; Whitley RJ
Intervirology; 1988; 29(1):39-49. PubMed ID: 2838428
[TBL] [Abstract][Full Text] [Related]
2. Passive immunization with monoclonal antibodies against herpes simplex virus glycoproteins protects mice against herpetic ocular disease.
Metcalf JF; Koga J; Chatterjee S; Whitley RJ
Curr Eye Res; 1987 Jan; 6(1):173-7. PubMed ID: 3030642
[TBL] [Abstract][Full Text] [Related]
3. Passive transfer of anti-herpes simplex virus type 2 monoclonal and polyclonal antibodies protect against herpes simplex virus type 1-induced but not herpes simplex virus type 2-induced stromal keratitis.
Ritchie MH; Oakes JE; Lausch RN
Invest Ophthalmol Vis Sci; 1993 Jul; 34(8):2460-8. PubMed ID: 8392037
[TBL] [Abstract][Full Text] [Related]
4. Protective immunity against herpetic ocular disease in an outbred mouse model.
Metcalf JF; Whitley RJ
Curr Eye Res; 1987 Jan; 6(1):167-71. PubMed ID: 3030641
[TBL] [Abstract][Full Text] [Related]
5. Previous immunization of mice with herpes simplex virus type-1 strain MP protects against secondary corneal infection.
Sandstrom IK; Foster CS; Wells PA; Knipe D; Caron L; Greene MI
Clin Immunol Immunopathol; 1986 Aug; 40(2):326-34. PubMed ID: 3013476
[TBL] [Abstract][Full Text] [Related]
6. Prevention of herpes simplex virus induced stromal keratitis by a glycoprotein B-specific monoclonal antibody.
Krawczyk A; Dirks M; Kasper M; Buch A; Dittmer U; Giebel B; Wildschütz L; Busch M; Goergens A; Schneweis KE; Eis-Hübinger AM; Sodeik B; Heiligenhaus A; Roggendorf M; Bauer D
PLoS One; 2015; 10(1):e0116800. PubMed ID: 25587898
[TBL] [Abstract][Full Text] [Related]
7. Prevention of herpes keratitis by monoclonal antibodies specific for discontinuous and continuous epitopes on glycoprotein D.
Lousch RN; Staats H; Oakes JE; Cohen GH; Eisenberg RJ
Invest Ophthalmol Vis Sci; 1991 Sep; 32(10):2735-40. PubMed ID: 1716618
[TBL] [Abstract][Full Text] [Related]
8. Effective antibody therapy in herpes simplex virus ocular infection. Characterization of recipient immune response.
Lausch RN; Staats H; Metcalf JF; Oakes JE
Intervirology; 1990; 31(2-4):159-65. PubMed ID: 2373609
[TBL] [Abstract][Full Text] [Related]
9. Use of monoclonal antibodies for analysis of antibody-dependent immunity to ocular herpes simplex virus type 1 infection.
Rector JT; Lausch RN; Oakes JE
Infect Immun; 1982 Oct; 38(1):168-74. PubMed ID: 6292092
[TBL] [Abstract][Full Text] [Related]
10. Herpes simplex virus glycoprotein D. Protective immunity against murine herpetic keratitis.
Inoue Y; Ohashi Y; Shimomura Y; Manabe R; Yamada M; Ueda S; Kato S
Invest Ophthalmol Vis Sci; 1990 Mar; 31(3):411-8. PubMed ID: 2318582
[TBL] [Abstract][Full Text] [Related]
11. Protection against lethal challenge of BALB/c mice by passive transfer of monoclonal antibodies to five glycoproteins of herpes simplex virus type 2.
Balachandran N; Bacchetti S; Rawls WE
Infect Immun; 1982 Sep; 37(3):1132-7. PubMed ID: 6290390
[TBL] [Abstract][Full Text] [Related]
12. Purification of herpes simplex virus glycoproteins B and C using monoclonal antibodies and their ability to protect mice against lethal challenge.
Roberts PL; Duncan BE; Raybould TJ; Watson DH
J Gen Virol; 1985 May; 66 ( Pt 5)():1073-85. PubMed ID: 2582080
[TBL] [Abstract][Full Text] [Related]
13. Passive immune protection by herpes simplex virus-specific monoclonal antibodies and monoclonal antibody-resistant mutants altered in pathogenicity.
Kümel G; Kaerner HC; Levine M; Schröder CH; Glorioso JC
J Virol; 1985 Dec; 56(3):930-7. PubMed ID: 2415719
[TBL] [Abstract][Full Text] [Related]
14. Protective effects of anti-glycoprotein D monoclonal antibodies in murine herpetic keratitis.
Inoue Y; Ohashi Y; Watanabe H; Manabe R
Curr Eye Res; 1992 Jan; 11(1):53-60. PubMed ID: 1313753
[TBL] [Abstract][Full Text] [Related]
15. Passive immunization protects the mouse eye from damage after herpes simplex virus infection by limiting spread of virus in the nervous system.
Shimeld C; Hill TJ; Blyth WA; Easty DL
J Gen Virol; 1990 Mar; 71 ( Pt 3)():681-7. PubMed ID: 2156001
[TBL] [Abstract][Full Text] [Related]
16. Investigation of a sub-unit vaccine using an animal model of herpes simplex keratitis.
Harney BA; Easty DL; Skinner GR
Trans Ophthalmol Soc U K (1962); 1983; 103 ( Pt 3)():342-6. PubMed ID: 6324419
[TBL] [Abstract][Full Text] [Related]
17. Glycoprotein gB of herpes simplex virus expresses type-common and type-specific antigenic determinants in vivo.
Dix RD
J Med Virol; 1990 Mar; 30(3):192-5. PubMed ID: 1692872
[TBL] [Abstract][Full Text] [Related]
18. Immunomodulation of experimental murine herpes simplex keratitis: II. Glycoprotein D protection.
Foster CS; Sandstrom IK; Wells PA; Thompson P; Daigle J; Opremcak EM
Curr Eye Res; 1988 Nov; 7(11):1051-61. PubMed ID: 2854037
[TBL] [Abstract][Full Text] [Related]
19. Use of monoclonal antibody directed against herpes simplex virus glycoproteins to protect mice against acute virus-induced neurological disease.
Dix RD; Pereira L; Baringer JR
Infect Immun; 1981 Oct; 34(1):192-9. PubMed ID: 6271681
[TBL] [Abstract][Full Text] [Related]
20. Different mechanisms of protection by monoclonal and polyclonal antibodies during the course of herpes simplex virus infection.
Eis-Hübinger AM; Mohr K; Schneweis KE
Intervirology; 1991; 32(6):351-60. PubMed ID: 1657825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
